A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6765 in Healthy Male and Female Japanese and Caucasian Subjects

Trial Profile

A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6765 in Healthy Male and Female Japanese and Caucasian Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2014

At a glance

  • Drugs Lanicemine (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Acronyms JSAD/JMAD
  • Sponsors AstraZeneca
  • Most Recent Events

    • 17 Mar 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 17 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Dec 2008 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top